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HerpesKaposi's sarcoma-associated herpesvirus (KSHV) encodes a transcriptional repressor, K-bZIP. We previously
demonstrated that K-bZIP suppresses interferon (IFN)-β expression. Here, we provide evidence that K-bZIP
affects IFN signaling, resulting in impaired IFN-stimulated genes expression. Inhibition by K-bZIP is
independent of the phosphorylation of signal transducers and activators of transcription proteins or the
binding of the IFN-stimulated gene factor 3 to the IFN-stimulated responsive element. Relative to thewild-type
protein, K-bZIPK158R mutant exhibited reduced inhibitory activity, indicating that sumoylation on K158 is
likely important for this effect. A new sumoylation site present within a newly identiﬁed K-bZIP variant and
absent from the fully spliced K-bZIP was also identiﬁed. Furthermore, K-bZIP is acetylated on lysine residues
and CBP enhances K-bZIP acetylation. Combined with its ability to negatively modulate IFN-β production and
inhibit type I IFN signaling, K-bZIP represents a viral immunomodulator that contributes to curtail immune
defense mechanisms and favor KSHV's persistence.yResearch Center, RoomT1-49,
4G2. Fax: +1 418 654 2765.
lamand).
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Interferons (IFNs) form an important group of cytokines that are
best known for their ability to induce cellular resistance to virus
infection (Biron, 2001; Kotenko et al., 2003; Samuel, 2001; Taniguchi
and Takaoka, 2002). However, IFNs effects extend beyond their
antiviral roles and affect many other cellular functions, such as cell
growth in addition of their immunomodulatory activities. IFNs include
the type I IFN family (also termed the IFN- α/β family), type II IFN or
IFN-γ, and the type III IFN family (also called the IFN-λ family). IFNα/β
are major proteins that initiate an antiviral response, protect against
further viral infection, and modulate adaptative immune responses
(Kotenko and Pestka, 2000). Once secreted, IFN-α/β bind to a common
heterodimeric receptor (IFNAR1 and IFNAR2) whose intracellular
domains are associatedwith the Tyk2 and Jak1 protein tyrosine kinases
(JAKkinases), respectively (Platanias, 2005). The binding of IFN-α/β to
IFNAR results in the cross-activation of the JAK kinases that
phosphorylate IFNAR1, STAT1 and STAT2 (signal transducer and
activator of transcription). Then, phospho-STAT1, phospho-STAT2,
and a DNA binding protein, p48 (IRF9) assemble to form the IFN-
stimulated gene factor 3 (ISGF3) complex that migrates to the nucleus
where it binds to IFN-stimulated response elements (ISRE) found in the
promoter of numerous genes including MHC-1, 2′-5′ oligoadenylate
synthase (2′,5′-OAS), IRF7, ISG15, ISG56 and others to promotetranscription (Brierley and Fish, 2005; Darnell, 1997; Kotenko and
Pestka, 2000; Platanias, 2005; Schindler et al., 1992).
Most viruses have developed molecular mechanisms to circumvent
the IFN response: interfering globallywith host-cell gene expression and/
or protein synthesis; decreasing IFN induction by limiting the production
of viral pathogen-associated molecular patterns and/or by speciﬁcally
blocking IFN induction cascades; inhibiting IFN signaling; blocking the
action of IFN-induced enzymes with antiviral activity; and having a
replication strategy that is (largely) insensitive to the action of IFN
(Goodbourn et al., 2000; Randall and Goodbourn, 2008). Kaposi's
sarcoma-associated herpesvirus (KSHV), an oncogenic gammaherpes-
virus linked with Kaposi's sarcoma, primary effusion lymphomas (PEL),
andmulticentric Castleman's disease (Cesarman et al., 1995; Chang et al.,
1994; Dupin et al., 1995, 1999; Soulier et al., 1995), has developed
different strategies to counteract the IFN pathway. KSHV produces
interferon-regulatory factor (IRF) orthologues, such as vIRF3 and vIRF1
(Cunningham et al., 2003). vIRF3 interacts with IRF7 (Joo et al., 2007) and
interfere with the activation of both the IFN-β promoter and IFN-
responsive genes (ISG) (Offermann, 2007; Rezaee et al., 2006), whereas
vIRF1 is able to block the recruitment of the CBP/p300 coactivators
towards IRF3 (Lin et al., 2001). The ORF45-encoded viral protein, ORF45,
and the ORF50-encoded viral protein, replication and transcription
activator (RTA) have been shown to speciﬁcally inhibit IRF7 (Coscoy,
2007; Yu et al., 2005). LANA-1 interfereswith IFN-β gene transcription by
competing with IRF3 for binding to the IFN-β promoter (Cloutier and
Flamand, 2010). Lastly, vIRF2 inhibits the expression of ISG controlled by
IRF1, IRF3 and ISGF3 by binding to p300 (Burysek et al., 1999; Fuld et al.,
2006).
Fig. 1. K-bZIP represses ISG56 and 2′,5′-OAS gene activation triggered by Sendai virus.
HEK 293T cells were transfected with increasing amount of K8 expression vector. DNA
amount was kept constant by adding empty pCMV3T vector. Twenty-four hours later,
the cultures were infected (or not) with SeV for 16 h, cells were harvested and total
RNA extracted using the Trizol reagent. RNA samples were treated with DNAse I and
analyzed for (A) ISG56 and (B) 2′,5′-OAS mRNA by RT-QPCR as described in materials
andmethods. Results are expressed asmean (triplicate) fold induction+/− SD relative
to pCMV3T control-transfected cells after normalization of samples using GAPDH
mRNA expression levels. Results are representative of three independent experiments.
* pb0.05. C) K-bZIP and β-actin proteins in whole-cell extracts were determined by
Western blots.
15S. Lefort et al. / Virology 408 (2010) 14–30KSHVORFK8encodes a viral protein that is expressed early during the
lytic replication cycle of KSHVandessential for the viral cycle progression
in PEL cells (Lefort and Flamand, 2009; Lin et al., 1999). K-bZIP, themajor
product of ORFK8, is a nuclear homodimerizing protein of 237 amino
acids (Izumiya et al., 2005; Polson et al., 2001; Portes-Sentis et al., 2001).
Additional and naturally occurring splice variants of K-bZIP thought to
play a role in K-bZIP regulation have been reported (Lin et al., 2003). K-
bZIP colocalizes with PML oncogenic domains and viral replication
compartments, and have been reported to play a role in viral DNA
replication (AuCoin et al., 2004; Lin et al., 2003;Wuet al., 2001). K-bZIP is
able to negatively regulate the activity of RTA on K8 and ORF57
promoters but not on the Pan promoter (Izumiya et al., 2003; Liao et al.,
2003). Sumoylation of lysine 158 has been described to be necessary for
the optimal transcriptional repression activity of K-bZIP (Izumiya et al.,
2005) while phosphorylation of threonine 111 downregulates the
activity of K-bZIP (Izumiya et al., 2005; Polson et al., 2001). K-bZIP
interacts and colocalizes with the transcriptional coactivator CREB-
binding protein (CBP) (Hwang et al., 2001). Interaction is dependent on
the basic region of K-bZIP and the cysteine/histidine-rich domain 3 of
CBP (Hwang et al., 2001). Interactions between K-bZIP and CBP, which
might lead to competition between K-bZIP and other transcription
factors for limited amounts of CBP,modulate CBP-mediated transcription
of promoters including AP-1 and nuclear factor (NF)-κB-responsive
elements (Hwang et al., 2001). We previously showed that K-bZIP binds
directly to the PRD III-I region of the IFN-β promoter and as a
consequence, causes a low-level of IFN-β gene transcription. In doing
so, K-bZIP prevents IRF3 from binding to the IFN-β promoter and
precludes the formation of the enhanceosome, required formaximal IFN-
β gene transcription (Lefort et al., 2007).
In the present work, we were interested in determining whether K-
bZIP of KSHV is able to interfere with the type I IFN signaling pathway.
Our results indicate that K-bZIP expression efﬁciently represses
activation of the 2′,5′-OAS and ISG15 genes in response to IFNα
stimulation. K-bZIP expression does not inﬂuence the phosphorylation
of STAT1 and STAT2 proteins nor does it interfere with the binding of
ISGF3 to the 2′,5′-OAS promoter. Our results also indicate that
overexpression of CBP reverses the K-bZIP-mediated repression of the
type I IFN signaling pathway and causes acetylation of K-bZIP on lysine
residues. Finally, sumoylation of K-bZIP on K158, but not its E3-SUMO
ligase activity, is essential for maximal K-bZIP repressor activity.
Results
K-bZIP inhibits Sendai virus’ activation of ISG56 and 2′,5′-OAS genes
Our previous observation that K-bZIP acts as a transcriptional
repressor of IFN-β gene expression (Lefort et al., 2007) lead us to
investigate the possibility that K-bZIP could also interfere with the
type I IFN signaling pathway. To test this hypothesis, we transfected
HEK 293T cells with increasing doses of a K8 expression vector, in the
absence or in the presence of Sendaï virus (SeV), as IFN inducer. As
shown in Fig. 1A and B, the expression of K-bZIP also led to ISG56 and
2′,5′-OAS genes inhibition in HEK 293T cells. We typically observed a
60% inhibition in the levels of mRNA of these genes in the presence of
K-bZIP. The inhibition of ISG56 and 2′,5′-OAS mRNA could result from
lower IFN production by K-bZIP expressing cells as previously
reported (Lefort et al., 2007) or alternatively (non mutually exclusive
possibilities), could result from an impaired IFN signaling cascade.
Type I interferon-signaling pathway is inhibited by K-bZIP
To test the hypothesis that K-bZIP interferes with IFN signaling,
HEK 293T cells were co-transfected with increasing doses of K8
expression vector and ISRE-luc reporter followed, 16 h later, by IFNα
(1000 U/ml) stimulation. Luciferase activity was measured after an
additional 24 h. As shown in Fig. 2A, IFNα efﬁciently activated theISRE promoter. Upon K-bZIP expression, luciferase activity dropped by
more than 60%, suggesting that K-bZIP interfered with ISGs activation.
This inhibition was K-bZIP dose-dependent. To conﬁrm these results,
HEK 293T cells were transfected with increasing doses of K8
expression vector in the absence or presence of IFNα (1000 U/ml),
and cells were analyzed for 2′,5′-OAS and ISG15 mRNA levels by RT-
QPCR (Fig. 2B and C), two genes responsive to interferon stimulation.
In the presence of K-bZIP, a 60–80% decrease in 2′,5′-OAS and ISG15
mRNA expression was observed. Similar results were obtained using
A549 cells (Fig. 2D), indicating that this effect is not restricted to HEK
293T cells. Lastly, we analyzed the kinetics of inhibition of IFNα-
stimulated genes by K-bZIP. HEK 293T cells were transfected with K8
expression vector or pCMV3T control vector for 24 h, then stimulated
with IFNα for 0, 4, 8, 16, and 24 h, after which 2′,5′-OAS (Fig. 2E) and
ISG15 (Fig. 2F) mRNA expressionwas determined by RT-QPCR. In cells
Fig. 2. K-bZIP represses type I interferon-signalingpathway.HEK293T (A–C) or A549 (D) cellswere transfectedwith increasing amounts ofK8 expressionvector. (A) Twenty-four hours later,
cells were stimulated with IFN alpha (1000 U/ml) for 16 h, cells were then resuspended in lysis buffer and luciferase activity determined. Results are expressed as mean (triplicate) fold
inductionof ISRE-luc activity±SDrelative to cells transfectedwith control plasmidandare representativeof three independent experiments. (B–D)Twenty-fourhours later, the cultureswere
stimulatedwith IFN alpha (1000 U/ml) for 16 h, total RNAwas isolated andprocessed for 2′,5′-OAS (B,D), or ISG15 (C)mRNA levels determinationbyRT-QPCR. (E and F)HEK293T cellswere
transfectedwithpCMV3TorK8expressionvector. Twenty-fourhours later, cellswere stimulatedwith IFNalpha(1000 U/ml) for 0, 4, 8, 16, and24 h,and total RNAwas isolatedandprocessed
for 2′,5′-OAS (E), or ISG15 (F) mRNA levels determination by RT-QPCR. Results are expressed as mean (triplicate) induction (n-fold)±SD relative to pCMV3T control-transfected cells after
normalization of samples with GAPDH mRNA expression. Results are representative of three independent experiments. * pb0.05; ** p b 0.01. K-bZIP and β-actin protein levels were
determined by Western blots.
16 S. Lefort et al. / Virology 408 (2010) 14–30transfected with the control vector, we observed a time-dependent
increase in 2′,5′-OAS and ISG15 mRNA expression. At all time points
examined, cells expressing K-bZIP had lower 2′,5′-OAS and ISG15
mRNA levels relative to control cells. For both genes tested, maximal
inhibition was recorded at peak gene induction, 24 h post IFNα
stimulation. Experiments conducted in the presence of actinomycin D
to determine the 2′,5′-OAS and ISG15 mRNA half-life, indicated that
K-bZIP does not affect the 2′,5′-OAS and ISG15 mRNA stability (data
not shown). These results suggest that type I IFN signaling pathway is
negatively affected by the presence of K-bZIP, at an early stage
following IFNα activation.
STAT phosphorylation and ISGF3 binding to ISRE element are not affected
by the presence of K-bZIP
Once secreted IFNα/β binds to the IFNAR receptor causing cross-
activation of the JAK kinases, which phosphorylate IFNAR1, STAT1 and
STAT2. This leads to the formation of the IFN-stimulated gene factor 3
(ISGF3) complex that migrates to the nucleus where it binds to IFN-
stimulated response elements (ISRE) found in the promoter ofnumerous genes including 2′,5′-OAS. First, to determine whether K-
bZIP interfered with the phosphorylation of STAT1 and STAT2, HEK
293T cells were transfected with K8 expression vector or control
vector and stimulated for 8 h with IFNα (Fig. 3A). In the absence of
IFNα stimulation we were not able to detect any phosphorylated
STAT1/2, unlike IFNα-stimulated cells. As shown in Fig. 3A, increasing
doses of K8 had no effect on the phosphorylation status of STAT1 or
STAT2. Knowing that STAT phosphorylation is not affected, we next
tested whether K-bZIP could interfere with the binding of ISGF3 to the
2′,5′-OAS promoter. Double-stranded oligonucleotides containing the
ISRE region of 2′,5′-OAS promoter were incubated with nuclear
extracts from resting and IFNα-stimulated HEK 293T cells transfected
with increasing doses of K8 expression vector. Proteins bound to the
2′,5′-OAS promoter were analyzed by Western blotting. As shown in
Fig. 3B, K-bZIP does not bind in the ISRE region of the 2′,5′-OAS
promoter. Binding of STAT1, STAT2, and IRF9 was effectively induced
by IFNα stimulation. K-bZIP had no effect on the ability of ISGF3
complex to bind to the 2′,5′-OAS promoter (Fig. 3B). Similar results
were obtained with nuclear extracts from A549 cells transfected with
pCMV3T control vector or K8 expression vector (−/+ IFN) (data not
Fig. 3. K-bZIP does not affect STAT phosphorylation, nor the binding of ISGF3 to ISRE element. (A) HEK 293T cells were transfected with increasing amounts of K8 expression vector.
Twenty-four hours post-transfection, the cells were stimulated with IFN alpha (1000 U/ml) for 8 h. Total cell extracts were made and analyzed by Western blot using speciﬁc
antibodies. (B) HEK 293T cells were transfected with increasing amounts of K8 expression vector. Twenty-four hours later, cells were stimulated with IFN alpha (1000 U/ml) for 8 h.
Nuclear extracts (N.E.) were made and tested for binding to dsDNA oligonucleotides containing the ISRE element of the 2′,5′-OAS promoter sequence. After the binding reaction,
proteins were eluted and analyzed by Western blot using speciﬁc antibodies. Nuclear extracts were also analyzed (5% of input used in the binding reaction) by Western blot to
determine the amount of each protein in the nuclear fraction.
17S. Lefort et al. / Virology 408 (2010) 14–30shown). We concluded from these studies that inhibition of type I IFN
signaling pathway by K-bZIP does not originate from impaired
phosphorylation of STAT proteins or an effect on the binding of
ISGF3 to the ISRE element.
Expression levels of K-bZIP in 293T and BCBL-1 cells
K-bZIP expression levels in transfected 293T cells were compared
to BCBL-1. Results (Fig. S1) suggest that transfected cells express
somewhat higher levels of K-bZIP than BCBL-1 cells. However, it
should kept in mind that while 293T cell transfection efﬁciency is
N85%, KSHV reactivation following TPA stimulation or doxycyclin
treatment (BCBL-1TRex-RTA) rarely exceeds 20% (Nakamura et al.,
2003; Zhao et al., 2007).
Sumoylation of K-bZIP
A previous report suggested that K-bZIP undergoes sumoylation in
PEL cells (Izumiya et al., 2005). Using RTA-inducible BCBL-1 cells
(Nakamura et al., 2003), we could successfully demonstrate the presence
of polysumoylated forms of K-bZIP once the lytic cycle has been engaged
(+doxycyclin) (Fig. 4A). Total cells extracts from BCBL-1 cells show the
presence of multiple bands reacting with the anti-K-bZIP antibody
suggesting the presence of multiple isoforms of K-bZIP. BJAB, a KSHV
negative cell line was used as control. In previous work, covalent
modiﬁcations of K-bZIP by SUMO-1, SUMO-2 or SUMO-3 were reported
to occur on a single site, K158 (Izumiya et al., 2005). In the present study,
we conﬁrm that K-bZIP is efﬁciently sumoylated by SUMO-1 andSUMO-3
(Fig. 4B). The ΔLZ mutant (splice variant II) is not sumoylated, as
previously reported (Izumiya et al., 2005). Unexpectedly however, our
K158R mutant was sumoylated by both SUMO-1 and SUMO-3 as
efﬁciently as wild-type K-bZIP. It turns out that in the work of Izumiya
et al. (2005), all experiments were conducted using an expression vector
encoding a fully spliced version of K-bZIP (K-bZIP-I). In contrast, our K8
expression vector is derived from genomic KSHV DNA and therefore
potentially encodes most splice variants of K-bZIP previously described
(Fig. 4C). In the type III splice variant, the 147 nucleotide intron located
between exon I and II is unspliced yielding a protein of similar size (239
aa) to that of wild-type K-bZIP (237 aa). The reading frame ismaintainedall theway through the end of exon II where, in the absence of additional
splicing events, a stop codon is encountered. In this splice variant the
SUMOVKAEconsensusmotif surroundingK158 is lostwhile anewSUMO
consensusmotif surroundingK207 (LKAE) is generated (Fig. 4CandD). To
determine whether K207 could represent a new SUMO acceptor site, we
generated a K207Qmutant.We opted to generate a K207Qmutant rather
that typical K207R mutant to preserve the splice acceptor site allowing
expression of all splice variants. Mutation of the K-bZIP-III K207Q had
little effect onK-bZIP sumoylationwithdetectionof SUMO-1andSUMO-3
conjugated forms of K-bZIP (Fig. 4E). Presumably, these represent K-bZIP
type I splice variant that are sumoylated on K158. We next proceed to
generate a double mutant with K158R from the type I splice variant and
K207Q from the type III splice variant. As shown in Fig. 4D, the double
K158R/K207Q mutant could no longer be sumoylated by SUMO-1 or
SUMO-3. These results point out to the identiﬁcation of a previously
unrecognized sumoylation site within the intron located between exon I
and exon II of K8 mRNA. Since the leucine zipper from exon III appears
important for sumoylation of K-bZIP to occur and that splice variant III
does not encode the leucine zipper, we suspected that at least one
additional splicing event must occur between exons II-III for it to be
translated in frame with exon II. In support, upon transfection of our K8
vector into 293T cells we could detect, using primers located in exons I
and III, amplicons of sizes corresponding to the 4 isoforms presented
under Fig. 4C (Fig. S2). When these amplicons were sequenced, we
conﬁrmed the presence of the three previously reported K-bZIP splice
variants (I-II-III) as well as a fourth (IV) and previously unrecognized K-
bZIP splice variant (Fig. 4C).Type I interferon-signaling pathway inhibition is inﬂuenced by K-bZIP
sumoylation status
A previous report suggested that the repressive activity of K-bZIP
on RTA is linked to its sumoylation status (Izumiya et al., 2005). To
identify the K-bZIPmotifs involved in type I IFN signaling inhibition by
K-bZIP, we tested several mutants of K-bZIP in our system. As shown
in Fig. 5A, IFNα stimulation lead to increased 2′,5′-OAS mRNA in
control-transfected cells. As presented above, wild-type K-bZIP
efﬁciently blocked (70%) IFNα-activation of the 2′,5′-OAS gene.
Similarly, transfection of the K8T111A/S167A vector, encoding a
18 S. Lefort et al. / Virology 408 (2010) 14–30phosphorylation-negative mutant of K-bZIP, had the same negative
impact on IFNα stimulation. On the other hand, expression of the
K158R mutant had little effect of IFN-stimulated 2′,5′-OAS gene
expression (Fig. 5A). A similar ﬁnding was obtained with the K8ΔLZ
mutant. Although the K8ΔLZ still contains K158, studies by Izumiya etFig. 4. SumoylationofK-bZIP inTREx-BCBL-1-Rta andHEK293T cells. (A)BJABandTREx-BCBL-1
with 1 μg/ml doxycyclin for 24 h. Total cell extractsweremade, immunoprecipitatedwith anti-
were transfectedwith K8 or K8mutants, and SUMO-1 or SUMO-3 expression vectors. Thirty-six
and analyzed by Western blot using anti-his and anti-myc antibodies. (C) Schematic represen
corresponding K-bZIP proteins. Exons are represented as open boxes. Summary of three types
shown as solid lines. Dashed rectangle surrounding ORFK8 indicates the cloned genomic DNA us
VKAE,where K represents the lysine 158. The SUMOacceptor site identiﬁed in this paper is show
aa, amino acids; kDa, kilodaltons.Adapted fromLinet al. (1999) (D)Sequenceof the clonedgeno
(LKAE) SUMO acceptor sites. Triangled nucleotides show difference in our cloned K8 relative t
mutants, and SUMO-1 or SUMO-3 expression vectors. Thirty-six hours later, total cell extracts w
using anti-his and anti-myc antibodies.al. (2005)) indicated that this mutant is not sumoylated, a result that
we have conﬁrmed (Fig. 4B). These results argue in favor of a potential
role for sumoylation in K-bZIP inhibition of type I IFN signaling.
Considering that we have identiﬁed a new sumoylation site within K-
bZIP, the impact of mutating this SUMO acceptor site in relation toWT-Rta cellswerenucleofectedwith SUMO-3expressionvector. After 16 h, cellswere induced
K-bZIP antibody and analyzed byWesternblot using anti-myc antibody. (B)HEK 293T cells
hours later, total cell extracts weremade, immunoprecipitatedwith anti-K-bZIP antibody
tations of K-bZIP showing the genomic location of K8, K8 gene, K8 mRNA isoforms and
of cDNAs reported by Lin et al. (1999) and proteins corresponding to each transcript are
ed in this paper. The SUMOacceptor site previously described by Izumiya et al. is shown as
n as LKAE,where K represents the lysine 207. ZIP, leucine zipper; *, translation stop codon;
micportion of K8, showing exons, amino acid translation, lysine 158 (VKAE) and lysine207
o Genbank accession number U75698. (E) HEK 293T cells were transfected with K8 or K8
ere made, immunoprecipitated with anti-K-bZIP antibody and analyzed byWestern blot
Fig. 4 (continued).
19S. Lefort et al. / Virology 408 (2010) 14–30K-bZIP and their effects on ISG were determined. HEK 293T cells were
transfected with increasing doses of WT of various mutant expression
vectors of K8 in the absence or in the presence of IFNα. ISRE promoter
activation was measured using the ﬁreﬂy luciferase reporter (Fig. 5B),
or ISG15 mRNA levels were analyzed by RT-QPCR (Fig. 5C). We
observed that wild-type K-bZIP was able to inhibit, in a dose-
dependent manner, the activation of genes by IFNα (Fig. 5B and C),
while the K-bZIPK158R mutant was less effective in doing so (Fig. 5B
and C). The K207Qmutant proved as effective as WT K-bZIP while theK158R/K207Qmutant behaved as the K158Rmutant (Fig. 5B). Finally,
to demonstrate the importance of K158 sumoylation for this effect, we
tested the effects of Senp1, a SUMO speciﬁc protease (Mukhopadhyay
and Dasso, 2007), and Ubc9-C93S, a dominant-negative form of the E2
SUMO conjugating enzyme (Girdwood et al., 2003), on the ability of
K-bZIP to suppress 2′,5′-OAS gene activation following IFN stimula-
tion. As shown in Fig. 5D, IFNα activation of 2′,5′-OAS gene was not
inﬂuenced by the presence of Senp1 or Ubc9-C93S, when cells were
transfected with control or mutant K8 (K158R, K207Q and K158R/
Fig. 4 (continued).
20 S. Lefort et al. / Virology 408 (2010) 14–30K207Q) expression vectors. However, we observed that K-bZIP could
no longer inhibit the activation of the 2′,5′-OAS gene in response to
IFN when Senp1 or Ubc9-C93S were present with a near complete
restoration of 2′,5′-OAS gene activation observed. In all, these results
strongly suggest that sumoylation of K-bZIP K158 appears essential
for the ability of K-bZIP to inhibit type I IFN signaling.
Overexpression of CBP reverses the K-bZIP-mediated repression of the
type I IFN signaling pathway and causes acetylation of K-bZIP
Onemechanism by which K-bZIP causes transcriptional repression
is through the sequestration of CBP (Hwang et al., 2001) by competing
with limited amounts of cellular CBP. We could successfully
demonstrate (Fig. S3) that K-bZIP physically interacts under in vivo
conditions with the C/H3 domain of CBP (1677–1897), in accordance
with in vitro pull-down assays reported by Hwang et al. (2001). To
determine whether the inhibitory effects of K-bZIP on the type I IFN
signaling pathway also involved CBP sequestration, we co-expressed
K-bZIP together with increasing amounts of a CBP expression vector
and monitored 2′,5′-OAS mRNA expression in response to IFNα
stimulation by RT-QPCR. As shown in Fig. 6A, in the absence of K-bZIP,
overexpression of CBP had no impact on IFNα activation of 2′,5′-OAS
gene in control-transfected cells. On the other hand, adding increasing
quantities of CBP expression plasmid negated the inhibitory effect of
K-bZIP on 2′,5′-OAS gene activation by IFNα. This reversal of inhibition
was CBP dose-dependent and near complete restoration of IFN
activation at the highest dose of CBP used. These results suggest
that CBP sequestration by K-bZIP is one mechanism by which K-bZIP
interferes with type I IFN signaling pathway. Another possibility could
be that CBP, which is known for its histone acetyl-transferase (HAT)
activity (Chan and La Thangue, 2001), may modify the acetylation
status of K-bZIP. Whether K-bZIP is acetylated has not been reported.
To verify this possibility, BCBL-1 cells were treated with TPA andbutyric acid to induce the lytic cycle after which K-bZIP was
immunoprecipitated with anti-K-bZIP antibodies and analyzed by
western blot for acetylated forms using antibodies speciﬁc for
acetylated lysine residues (Fig. 6B). BJAB cells were used as control
cells. At the 24 h timepoint, we could detect the presence of acetylated
K-bZIP that migrated just below the IgG heavy chain in BCBL-1 cells.
Such band was absent from BJAB cells. To conﬁrm this result, HEK
293T cells were transfected with or without CBP or pCAF expression
vectors, in presence of K8 expression vector. Total cell extracts were
immunoprecipitated with anti-K-bZIP antibodies and analyzed by
Western blot using speciﬁc anti-acetylated-lysine antibodies (Fig. 6C).
In presence of CBP, we observed an acetylated form of K-bZIP, which is
not present in the absence of CBP overexpression. Furthermore, we
did not notice any acetylated form of K-bZIP in the presence of pCAF
(p300/CBP-associated factor), which is also a HAT (Workman and
Kingston, 1998). This result suggests that CBP is able to modify K-bZIP
to a K-bZIP acetylated form. Acetylation by CBP is somewhat speciﬁc,
as we did not observe any modiﬁcation in the presence of pCAF. We
also investigated if this K-bZIP acetylation could be affected by histone
deacetylases (HDAC). HEK 293T cells were transfected with or
without HDAC1, HDAC4 or SIRT1 (Sirtuin1) vectors, in presence of
CBP and K-bZIP, then total cell extracts were immunoprecipitated
with anti-K-bZIP antibodies and analyzed by Western blot using
speciﬁc anti-acetylated-lysine antibodies. We did not observe any
major impact on K-bZIP acetylation with these HDACs (data not
shown). The effects of twoHDAC inhibitors, TSA, which is a potent and
speciﬁc class I/II HDAC inhibitor and nicotinamide, which is a class III
HDAC inhibitor (Landry et al., 2000; Sauve and Schramm, 2003, 2004;
Smith et al., 2000), were also tested. As shown in Fig. 6D, in the
absence or presence of CBP, TSA and Nicotinamide lead to a minor
increase in K-bZIP acetylation. Together, these results suggested that
CBP is the major component responsible for K-bZIP acetylation, and
no evidence was found for a deacetylation process. In order to identify
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transfected HEK 293T cells with CBP expression vectors together with
K8, K8ΔLZ, K8K158R, or K8T111A/S167A expression vectors. As
shown in Fig. 6E, CBP co-expression leads to acetylation of wild-type
K-bZIP, K-bZIPK158R and K-bZIPT111A/S167A. These results demon-
strate that neither the K158 sumoylation status nor the phosphorylation
status of K-bZIP is essential for K-bZIP acetylation. However, the K-
bZIPΔLZ is much less efﬁciently acetylated (barely detectable) in the
presence of CBP (Fig. 6E). These results suggest that either there is at
least one acetylation site in the bZIP domain, or that bZIP domain is
essential to the binding of K-bZIP with an acetylation effector. The
acetylation status of the K207Q and K158R/207Q mutants was studied
and found to be similar to that of WT K-bZIP (Fig. 6F). In contrast, the K-
bZIPΔLZK207Q was very inefﬁciently acetylated, conﬁrming the above
result and suggesting the importance of the leucine zipper for this event
to take place. Knowing that K-bZIP can interact with CPB (Hwang et al.,
2001), we analyzed whether a correlation between K-bZIP-CBP
interaction and acetylation of K-bZIP could be made. Expression vectors
encoding K-bZIP, K-bZIPK158R or K-bZIPΔLZ were transfected along
with CBP expression vectors after which K-bZIP proteins were
immunoprecipitated followed by western blot for CBP. As presented
under supplementary Fig. 2, K-bZIP andK-bZIPK158R interactwith CBP2
while K-bZIPΔLZ does not, suggesting that interaction with CBP is
essential for K-bZIP acetylation.
Using mass spectroscopy (LC/MS/MS) we have identiﬁed one
acetylated residue, K145, which lies outside the bZIP domain of K-bZIP.
To extend these results, a series of K-bZIP mutants were tested: K-
bZIPK194R and K-bZIPK209R, which contain mutated lysines in the
bZIP domain, and K-bZIPK145R. Western blots from HEK 293T cells
expressing CBP and wild-type or mutated indicate that these mutants
are as efﬁciently acetylated as wild-type K-bZIP (Fig. S4). These results
provide evidence that K-bZIP is likely acetylated by CBP on several
lysine residues and that the bZIP domain is important for the
interaction with proteins such as CBP that are involved in the
acetylation process.
K-bZIP acts as a wide-repressor agent on multiples promoters
The results obtained so far suggest that K-bZIP inhibits the type I
IFN signaling pathway, independently of the classical Jak/STAT
cascade. To determine if this inhibition could be observed for other
pathways, we next tested the inhibitory potential of K-bZIP on cells
stimulated with IFNλ, TNFα, and IFNγ (Fig. 7A–C). First, HEK 293T
cells were transfected with increasing doses of K8 expression vector
alongwith a CBP expression vector, in the absence or presence of IFNλ
(100 ng/ml), and cells were analyzed for 2′,5′-OAS mRNA levels by
RT-QPCR. IFNλ also signals via ISGF3 complex (Kotenko et al., 2003).
We observed more than a 50% decrease in 2′,5′-OAS mRNA levels, in
the presence of K-bZIP (Fig. 7A). As for IFNα, this repression could be
reversed by CBP, suggesting a commonality for K-bZIP mode of action
in both pathways. Two additional pathways, which signal differently
than type III and I IFN were tested (Li and Lin, 2008; Pestka et al.,
2004). Again, the results indicate that K-bZIP is capable of inhibiting
the TNFα (Fig. 7B) and IFNγ (Fig. 7C) activation of IL8 and CXCL9,
respectively. CBP could reverse the inhibitory effect of K-bZIP on TNFα
stimulation (Fig. 7B). Finally, we tested the hypothesis that the
widespread repressor activity associated with K-bZIP might be linked
to variations in cellular HAT activity. HEK 293T cells were transfected
with control, K8 and CBP expression vectors and stimulated for 16 h
with IFNα (Fig. 7D). Total cell extracts were made and analyzed for
HAT activity. Relative to control cells, K-bZIP expressing cells
displayed a statistically signiﬁcant 20% decrease in HAT activity.
IFNα stimulation had no effect on HAT activity while, as expected, CBP
overexpression increased basal HAT activity by 25%. When K-bZIP and
CBP were co-expressed, HAT activity was restored to and slightly
above the level of control cells. These results suggest an inversecorrelation between the levels of cellular HAT activity and the
repressor abilities of K-bZIP and could explain how this viral protein
can interfere with the transcription of multiple genes activated by
distinct pathways.
A very recent report indicated that K-bZIP is a functional SUMO-E3
ligase capable of promoting SUMO-2/3 sumoylation of proteins
including itself (Chang et al., 2010). Considering that CBP transcriptional
activity can be negatively modulated through sumoylation (Kuo et al.,
2005), the hypothesis that K-bZIPmay repress transcription through its
E3-SUMO ligase function was considered. A SUMO-interacting motif
(SIM) located between aa 72–76 (within exon I) was found important
for the ability of K-bZIP to induce sumoylation. To determine whether
the SUMO-E3 ligase function was required for K-bZIP mediated
inhibition of IFN-α mediated gene activation, we generated the K-
bZIPL75A mutant, reported to have lost all SUMO-E3 ligase activity
(Chang et al., 2010). As shown in Fig. 8, the K-bZIPL75A mutant
displayed equally potent inhibitory activity as wild-type K-bZIP, unlike
the K-bZIPK158R that has lost most of its activity. These results suggest
to us that the SUMO-E3 ligase activity of K-bZIP is not required for the
repressive activity of K-bZIP and that SUMO-E3 ligases, other than K-
bZIP itself, can sumoylate K-bZIP.
Discussion
Interferons are extremely powerful antiviral molecules that are
capable of controlling many viral infections in the absence of speciﬁc
immunity. Despite this, certain viruses can efﬁciently replicate and
cause diseases in vivo, because they have evolved immune evasion
strategies that can, at least partially, circumvent IFNs’ actions (Randall
and Goodbourn, 2008). Several proteins of KSHV have been described
as having such properties. These include four proteins referred to as
viral IRFs (Offermann, 2007), K3, K5 (Li et al., 2007), RTA (Yu et al.,
2005), LANA-1 (Cloutier and Flamand, 2010) and ORF45 (Zhu et al.,
2002). The K-bZIP protein of KSHV is described as a potent
transcriptional repressor (Izumiya et al., 2005; Liao et al., 2003). We
previously reported that K-bZIP prevents IRF3 frombinding to the IFN-β
promoter and precludes the formation of the enhanceosome, required
for maximal IFN-β gene transcription (Lefort et al., 2007). This
inhibition is the consequence of the direct binding of K-bZIP to the
PRD III-I region of the IFN-β promoter. In the present study, we provide
evidence that K-bZIP is able to interfere with the type I IFN signaling
pathway. First, when K-bZIP is expressed in cells that are stimulated
with the IFN-β inducer Sendaï virus, it behaves as a potent inhibitor of
2′,5′-OAS and ISG56 gene transcription. Second, K-bZIP inhibits IFN-
activated cellular ISGs as well as IFN-responsive promoter reporter
constructs, in a dose-dependent manner. We routinely observed
reductions of 60% or greater in IFNα-induced 2′,5′-OAS gene activation
in the presence of K-bZIP. Moreover, our data indicate that K-bZIP is
able to act early on the IFN signaling pathway, as we could see
inhibition of ISG15 mRNA at 4 h post IFN stimulation. Third, we
observed that K-bZIP inhibition of the type I IFN signaling pathway does
not affect STAT proteins phosphorylation. Furthermore, in response to
IFN stimulation, the quantity of ISGF3 that reached the nucleus and
capable of binding to the 2′,5′-OAS promoter is similar in the absence or
in the presence of K-bZIP, indicating that K-bZIP acts in a different
mechanism as the one it uses to repress IFN-β gene transcription (Lefort
et al., 2007). The absence of K-bZIP binding to the 2′,5′-OAS promoter
conﬁrmed this observation. Thus, our results indicate that inhibition of
the type I IFN signaling pathway by K-bZIP occurs beyond STAT proteins
phosphorylation and of the ISGF3 binding to the promoters of IFN-
responsive genes. However, it is now becoming increasingly apparent
that the sole activation of the Jak–STAT pathway is not sufﬁcient to
account for all of the biological activities of IFNs. Some of these
pathways operate independently of the Jak–STAT pathway, whereas
others cooperate with STATs to optimize the transcriptional regulation
of target genes (Platanias, 2005). For example, p38α is phosphorylated
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Fig. 5. Sumoylation of K-bZIP is important for type I IFN signaling defect. (A) HEK 293T cells were transfected with K8 or K8 mutant expression vectors. Twenty-four hours later, cells
were stimulated with IFN alpha (1000 U/ml) for 16 h, total RNA was isolated and processed for 2′,5′-OAS gene expression by RT-QPCR. (B) HEK 293T cells were transfected with
increasing amounts of K8 or K8 mutant expression vectors. Twenty-four hours later, cells were stimulated with IFN alpha (1000 U/ml) for 16 h, and cells were resuspended in lysis
buffer and luciferase activity determined. Results are expressed as mean (triplicate) fold induction in ISRE-luc activity±SD relative to cells transfected with control plasmid. (C) HEK
293T cells were transfected with increasing amounts of K8 or K8K158R followed by total RNA extraction and processing for ISG15 gene expression by RT-QPCR. (D) HEK 293T cells
were transfected with or without K8 or K8 mutant expression vectors and Senp1 or Ubc9-C93S expression vectors. Twenty-four hours later, cells were stimulated with IFN alpha
(1000 U/ml) for 16 h, total RNA was isolated and processed for 2′,5′-OAS gene expression by RT-QPCR. Results are expressed as mean (triplicate) induction (n-fold)±SD relative to
pCMV3T control-transfected cells after normalization of samples with GAPDH mRNA expression. Results are representative of three independent experiments. * pb0.05; ** pb0.01.
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cell lines (Goh et al., 1999; Uddin et al., 1999). In addition, the use of a
pharmacological inhibitor of p38 can block IFNα-dependent transcrip-tion of genes that are regulated by ISRE (Uddin et al., 1999). Such effects
did not affect STAT1 and STAT2 tyrosine phosphorylation, the formation
of the mature ISGF3 complex and the binding of this complex to ISRE,
Fig. 6. CBP is important to reverse the K-bZIP inhibition of type I IFN signaling. (A) HEK 293T cells were transfected with or without K8 expression vector and increasing amounts of CBP
expression vector. Twenty-four hours later, cells were stimulated with IFN alpha (1000 U/ml) for 16 h, total RNA was isolated and processed for 2′,5′-OAS gene expression by RT-QPCR.
Results are expressed asmean (triplicate) induction (n-fold)±SD relative to pCMV3T control-transfected cells after normalization of samples with GAPDHmRNA expression. Results are
representative of three independent experiments. * pb0.05. (B) BJAB or BCBL-1were stimulatedwith 20 ng/ml PMA and 0.3 mMbutyric acid for 6 and 24 h. Total cell extracts weremade,
immunoprecipitatedwith anti-K-bZIP antibody and analyzed byWestern Blot using speciﬁc anti-acetylated-lysine antibody. (C–F) HEK 293T cells were transfectedwith K8 or K8mutant
expression vectors and with or without CBP expression vector. Thirty-six hours later, total cell extracts were made, immunoprecipitated with anti-K-bZIP antibody and analyzed by
Western blot using speciﬁc anti-acetylated-lysine antibody. (C) K-bZIP is speciﬁcally acetylated by CBP, not by pCAF. (D) Impact of TSA (1 μM) and Nicotinamide (5 mM) on K-bZIP
acetylation. (E) K-bZIPΔLZ is not acetylated by CBP. (F) K-bZIPΔLZK207Q is not acetylated by CBP.
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independent (Uddin et al., 1999). There are also reports indicating that
type I IFNs activate the PI3K-signaling pathway downstream of Jaks, in a
STAT-independent manner (Uddin et al., 1997; Uddin et al., 2000).
Therefore, one possible explanation for the STAT-independent inhibi-
tion by K-bZIP that we observe, could be that K-bZIP interferes with at
least one of the other parallel pathways implicated in IFN biology.
Previous reports indicated that sumoylation of K158 is linked with
the repressive activity of K-bZIP (Izumiya et al., 2005). Our results
using the K-bZIPK158R mutant support this. Furthermore, the
expression of Senp1, a SUMO speciﬁc protease (Mukhopadhyay and
Dasso, 2007), or Ubc9-C93S, a dominant-negative form of endogenousUbc9 (Girdwood et al., 2003), completely reversed the ability of K-
bZIP to repress IFNα transcriptional activation of ISGs. Although K158
lies outside the leucine zipper (189–237), K-bZIP lacking the C-
terminal zipper motif (K-bZIPΔLZ) no longer interacts with Ubc9 and
does not appear to be sumoylated (Izumiya et al., 2005), a result that
we have conﬁrmed. The K-bZIPΔLZ is also reported to be inapt at
promoting transcriptional repression (Izumiya et al., 2005; Liao et al.,
2003). In accordance with these previous reports, our results showed
that K-bZIPΔLZ is not able to inhibit expression of genes activated by
IFNα stimulation. K-bZIP is phosphorylated on threonine 111 and
serine 167, and the phosphorylation of T111 has a negative impact on
K-bZIP repression activity (Izumiya et al., 2007). Our results indicating
Fig. 7. K-bZIP represses type III interferon, TNF alpha and type II interferon-signaling pathways. (A–C) HEK 293T cells were transfected with increasing amounts of K8 expression vector
with orwithoutCBP expression vector. Twenty-fourhours later, cellswere stimulatedwith (A) IFN lambda (100 ng/ml), (B) TNFalpha (20 ng/ml), or (C) IFNgamma(100 ng/ml) for 16 h,
and total RNA was isolated and processed for 2′,5′-OAS (A), CXCL8 (B), or CXCL9 (C) gene expression by RT-QPCR. Results are expressed as mean (duplicate) induction (n-fold)±SD
relative to pCMV3T control-transfected cells after normalization of samples with GAPDHmRNA expression. Results are representative of three independent experiments. (D) HEK 293T
cellswere transfected in the presence or in the absence of K8 and CBP expression vectors. Twenty-four hours post-transfection, cells were stimulatedwith IFN alpha (1000 U/ml) for 16 h.
Total cell extracts were made and analyzed for HAT activity. Results are expressed as mean (triplicate) percentage±SD relative to pCMV3T control-transfected cells. Results are
representative of three independent experiments. * pb0.05; ** p b 0.01.
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Fig. 8. K158 sumoylation of K-bZIP, not its E3 SUMO ligase function, is important for
type I IFN signaling defect. HEK 293T cells were transfected with increasing amounts of
K8 or K8 mutant expression vectors expression vectors. Twenty-four hours later, cells
were stimulated with IFN alpha (1000 U/ml) for 16 h, and cells were resuspended in
lysis buffer and luciferase activity determined. Results are expressed as mean
(triplicate) fold induction in ISRE-luc activity±SD relative to cells transfected with
control plasmid. * pb0.05; *** pb0.001.
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transcriptional inhibition of IFNα-mediated 2′,5′-OAS gene activation
compared to wild-type K-bZIP argue against a role for phosphoryla-
tion under such circumstances. Our data indicate that sumoylation of
K158R plays an important role in K-bZIP inhibition of 2′,5′-OAS gene
repression. The fact that we could not detect sumoylated-K-Zip in PEL
cells in the absence of SUMO overexpression raises the possibility that
the impaired repressive activity of the K-bZIPK158R mutant could
result from an altered property of K-bZIP, such as its ability to interact
with other proteins or bind DNA, rather than an effect due to the loss
of sumoylation of K158.
During this work we have identiﬁed a new and previously
unrecognized sumoylation site for K-bZIP. Previous studies suggested
that K158 was the only sumoylation site within K-bZIP (Izumiya et al.,
2005). However, unlike Izumiya et al. (2005), when we mutated this
site we could still observe efﬁcient K-bZIP sumoylation indicating that
other SUMO acceptor sites must exist. We have mapped this new
acceptor site to a lysine located within intron I. In fact, in the absence
of splicing events between exons I–II, intron I is translated in frame
with exon II. When this occurs, the K158 SUMO acceptor site, located
at the end of exon I, is destroyed (from VKAE to VKVG) while a new
functional sumoylation site (LKAE) is createdwith K207 becoming the
acceptor residue. According to Lin et al. (1999), such a transcript with
unspliced intron I can be experimentally observed. In this splice
variant (III) however, the splicing between exons II and III was not
observed causing a translational stop soon after exon II, yielding a
protein of 239 aa. From our results and those of Izumiya et al. (2005),we know that the leucine zipper is essential for sumoylation of K-bZIP
to occur. Considering that sumoylation of K207 still occurs when K158
is mutated to arginine, we suspected that a fourth variant existed
(Fig. 4C) in which a splice between exons II and III occurs, yielding a
protein of 286 aa containing the leucine zipper. The presence of this
new K-bZIP splice variant was conﬁrmed by sequencing. When a
similar analysis was done in BCBL-1, we only detected splice variants I
and II. The fact that we could not detect splice variant III argues that
this transcript is present in much lower abundance, as previously
reported (Lin et al., 1999). This is likely to be the case for splice variant
IV. The reason why Izumiya et al. (2005) have missed this site is
because the expression vector that they have used expresses a fully
spliced variant of K8. For our studies, we have cloned a genomic
segment of the KSHV genome allowing the multiple spliced
transcripts to be expressed, as it is the case during a natural infection.
As a consequence, in many of our experiments we detected several
isoforms of K-bZIP. Althoughmutation of K207 had no apparent effect
on K-bZIP functions, considering that other isoforms of K-bZIP,
including those with spliced intron I containing the mutated lysine
can be made, it is presently not possible to assess the importance of
K207 on K-bZIP. The use of vectors expressing a single isoform of K-
bZIP should allow this determination.
K-bZIP has already been reported to cause transcriptional
repression through the sequestration of CBP (Hwang et al., 2001;
Tomita et al., 2004). In the present work, we observed that
overexpression of CBP could reverse the K-bZIP-mediated repression
of the IFNα-activated 2′,5′-OAS gene. Tomita et al. (2004) identiﬁed K-
bZIP as an inactivator of TGF-β mediated transcriptional activation,
and that repression depended on the competition with Smad for
binding to CBP. K-bZIP is not however a universal transcriptional
repressor. In particular, K-bZIP has no effect on the RTA-mediated
activation of the PAN promoter (Izumiya et al., 2003). Recently, others
and we have reported that K-bZIP can activate several KSHV
promoters (Ellison et al., 2009; Lefort and Flamand, 2009). Our data
further indicate that IFNλ and TNFα transcriptional activation was
inhibited in the presence of K-bZIP, and that repression was reversed
with increasing amounts of CBP, suggesting that these effects are
possibly dependent of the sequestration or the inactivation of CBP by
K-bZIP. As a consequence, K-bZIP could interfere with acetylation of
nuclear histones, resulting in less chromatin remodeling in the
promoters of ISGs. Furthermore, K-bZIP is able to reduce HAT activity
supporting the idea that K-bZIP canmodulate CBP-dependent signaling
pathway. On the other hand, CBP, which is known to be a Histone
Acetyl-Transferase (Chan and La Thangue, 2001), could modify the
acetylation status of K-bZIP. Indeed, in normal conditions, K-bZIP is
poorly acetylated, but in the presence of CBP, its acetylation status is
greatly increased. Several lysine mutants of K-bZIP were analyzed with
no major impact on the acetylation status of K-bZIP recorded. This
suggests that K-bZIP contains multiple lysine residues that can be
acetylated in a manner analogous to p53, which contains several
acetylated residues having redundant effects (Tang et al., 2008).
Alternatively, K-bZIP may contain alternate acetyl acceptor sites than
lysines. To our knowledge this is the ﬁrst report demonstrating
acetylation of K-bZIP. Whether acetylation of K-bZIP plays a functional
role in K-bZIP's biology remains to be determined. Alternatively,
acetylation by CBP might compete for K-bZIP sumoylation at K158 in a
manner analogous towhat is observed for p300,MEF2 and others (Yang
andGregoire, 2007). Interestingly, Stankovic-Valentin et al. (2007) have
reported on the identiﬁcation of a ψKxEP motif that functions as an
acetylation/deacetylation-sumoylation switch that regulates the tran-
scriptional activity of the tumor suppressor gen HIC1. In K-bZIP, the
sumoylated lysine 158 resides within the ψKxEx motif that is not
reported to act as an acetyl acceptor site suggesting that competition
between these two post-translational modiﬁcations (sumoylation vs.
acetylation) is not responsible for the overriding effect of CBP. K-bZIP
acetylation could be a direct consequence of its binding to CBP. Unlike
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has lost its ability to bind to CBP, supporting thehypothesis that physical
interactions between K-bZIP and CBP are necessary for efﬁcient K-bZIP
acetylation to occur. Further studies are necessary to address the exact
roles of K-bZIP acetylation by CBP, to map the acetylation sites and to
identify the partners implicated in this mechanism.
We previously demonstrated that IFN β gene activation in
response to interferon inducers such as Sendai virus (SV) infection
or expression of retinoic acid inducible gene I, mitochondrial antiviral
signaling protein or TANK-binding-kinase 1 is severely impaired by
the presence of K-bZIP. In this report, our results indicate that K-bZIP
is also able to interfere with the type I IFN signaling pathway,
indicating that K-bZIP represents an important KSHV protein involved
in counteracting the innate immune response. During lytic infection
when abundant viral DNA and proteins are made, the innate
immunity cellular sensors would normally get turned on, leading to
IFN synthesis and release. However, through the concerted actions of
K-bZIP the antiviral effects of IFN are minimized. Our results therefore
identify new functions for K-bZIP that favor viral persistence.
Materials and methods
Cell culture
BJAB cells were purchased from ATCC (ATCC, Manassas, VA, USA)
and grown in RPMI-1640medium (Sigma-Aldrich Canada, ON, Canada)
supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS).
BCBL-1 cells (Renne et al., 1996) were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH,
andwere grown inRPMI-1640 containing10%HI-FBS. TREx-BCBL-1-Rta
cells were obtained from Jae U. Jung (Nakamura et al., 2003) and were
grown in RPMI-1640 containing 10% HI-FBS. A549 (ATCC) cells were
cultured in F12K/Ham medium (Hyclone, Logan, UT, USA) containing
10% HI-FBS. HEK 293T (ATCC) were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM) (Sigma-Aldrich Canada) containing 10% HI-
FBS.
Plasmids and constructs
Plasmids expressing HA-tagged wild-type K-bZIP, K-bZIPΔLZ (K-
bZIP-II) and K-bZIPK158R mutants were described previously
(Lefort et al., 2007). Additional K-bZIP mutants were generated by
site-directed mutagenesis (Stratagene, La Jolla, CA) using the following
primers: K-bZIP T111A forward: CTCTCTCACGCACCACCAAGAG, K-bZIP
T111A reverse: CTCTTGGTGGTGCGTGAGAGAG; K-bZIP-I/II S167A for-
ward: CAGTCACATGCTCCCACGCGAAAG, K-bZIP-I/II S167A reverse:
CTTTCGCGTGGGAGCATGTGACTG; K-bZIP K145R forward: CTAAGGCCA-
GACAGGGCGCAG, K-bZIP K145R reverse: CTGCGCCCTGTCTGGCCTTAG;
K-bZIP-I K194R forward: TAGAAGAAAGGGATGCACAA, K-bZIP-I K194R
reverse: TTGTGCATCCCTTTCTTCTA; K-bZIP-I K209R forward: GCACA-
TAGGGAACAGATTAT, K-bZIP-I K209R reverse ATAATCTGTTCCC-
TATGTGC; K-bZIP-III K207Q forward: GTCTCTTTACAGGCCGAAGTATG,
K-bZIP-III K207Q reverse: CATACTTCGGCCTGTAAAGAGAC; K-bZIP L75A
forward: GGTCATTGACGCTACAGCGCCTTC, K-bZIP L75A reverse:
GAAGGCGCTGTAGCGTCAATGACC, using the HA-tagged K8 plasmid as
template (Lefort et al., 2007). pISRELuc was purchased from Clontech
(Mountain View, CA, USA). Expression vectors for CBP1 and CBP2 (Lin
et al., 1998)were obtained from J. Hiscott andRongtuan Lin (LadyDavis
Institute, McGill University, Montreal Canada). pCAF expression vector
(Addgene plasmid 8941) was obtained from Yoshiro Nakatani (Dana-
Farber Cancer Institute, Boston, MA, USA) (Yang et al., 1996) and HA-
CBP expression vector was provided by Didier Trouche (Toulouse,
France). SUMO-3 cDNAwas obtained followingRT-PCR ampliﬁcation of
HeLa cell RNA as previously described (Gravel et al., 2004). SUMO-3
PCR product was ligated in frame with pCDNA3.1 eukaryotic myc-tagged vector. Plasmids expressing SUMO-1, Senp1 and Ubc9-C93S
were described previously (Gravel et al., 2004; Tomoiu et al., 2006).
Transfection
Transfections of HEK 293T were performed using the calcium
phosphate precipitation procedures. Cells were plated at 100000
cells/well (12-well plate) the day prior to transfection. Cells were
transfected with 0.1 μg of reporter plasmid and up to 2 μg of
expression vector per well, and brought to a total of 2.5 μg of DNA
per well for each condition with the pCMV3T control plasmid. Cells
were lysed 48 h after transfection and luciferase activity was
measured on a MLX Microtiter plate luminometer (Dynex Technol-
ogies, Chantilly, VA). Subconﬂuent A549 cells were transfected using
the TransiT-LT reagent (Mirus Corporation, Madison,WI) according to
the manufacturer's instructions and analyzed 24 h post-transfection.
Nucleofection
Five million of BJAB and TREx-BCBL-1-Rta cells were washed once
with PBS and resuspended in 100 μl of solution AB (mix of solution A
(88 mM KH2PO4, 14 mM NaHCO3, 2.2 mM glucose, pH 7.4) and
solution B (330 mM adenosine triphosphate (ATP), 590 mMMgCl2) in
a ratio 50:1). Plasmid DNA (5 μg) was added to cells suspension and
the cell/DNA suspensionwas transferred into AMAXA cuvettes (Lonza
Inc., Allendale, NJ, USA). Cells were nucleofected using the Nucleo-
fector II device (Lonza Inc.) and the T-001 program. Cells were
transferred into fresh complete RPMI medium and incubated at 37 °C,
5% CO2 for 16 h. Then, they were stimulated with 1 μg/ml doxycyclin
(Sigma-Aldrich Canada) for an additional 24 h.
Real-time quantitative PCR (RT-QPCR)
Total RNAwas extracted fromHEK 293T-transfected cells or A549-
transfected cells using TRIZOL reagent (Invitrogen, Ontario, Canada).
All RNA samples were treated with DNAse I to eliminate residual
genomic DNA prior to ampliﬁcation. Complementary DNA (cDNA)
was synthesized, and quantitative RT-PCR analysis was performed on
a Rotorgene apparatus (Montreal Biotech Inc, QC, Canada) using
SyBR®Greener technology (Invitrogen). The speciﬁcity of ampliﬁcation
was assessed for each sample by melting curve analysis. All transcripts
were normalized according to GAPDH housekeeping gene expression.
The following primer pairs have been used: GAPDH forward 5-
CGAGATCCCTCCAAAATCAA-3, GAPDH reverse 5-TTCACACCCATGAC-
GAACAT-3; IFNβ forward 5-AAACTCATGAGCAGTCTGCA-3, IFNβ reverse
5-AGGAGATCTTCAGTTTCGGAGG-3; 2′,5′-OAS forward 5- CAAGCTCAA-
GAGCCTCATCC-3, 2′,5′-OAS reverse 5-TGGGCTGTGTTGAAATGTGT-3;
ISG56 forward 5-CTTGAGCCTCCTTGGGTTCG-3, ISG56 reverse 5-GCTGA-
TATCTGGGTGCCTAAGG-3; ISG15 forward 5-CATGGGCTGGGACCT-
GACG-3, ISG15 reverse 5-CGCCAATCTTCTGGGTGATCTG-3; CXCL9
forward 5-GCATCATCTTGCTGGTTCTG-3, CXCL9 reverse 5-TAGGTGGA-
TAGTCCCTTGG-3; IL8 forward 5-GTGCAGTTTTGCCAAGGAGT-3, IL8
reverse 5-CTCTGCACCCAGTTTTCCTT-3.
Cell extracts
HEK 293Twere transfectedwith K8 expression vectors using calcium
phosphate in 6-well plates. Thirty-six hours after transfection, cells were
washed with PBS (137 mM NaCl, 3 mM KCl, 6.5 mM Na2HPO4, 0.5 mM
KH2PO4, pH 7.4), collected by scraping and centrifuged at 3000× g for
1 min. Whole-cell extracts were prepared by resuspension of cells in a
RIPA buffer (50 mM Tris–HCl, pH 8, 150 mM NaCl, 5 mM EDTA, 1 mM
DTT, 0.1% SDS, 0.5% deoxycholic acid, 1% Nonidet P-40, 1 mMN-
ethylmaleimide (NEM) and protease inhibitor mixture (Roche Diagnos-
tics)) and incubated for 45 min under gentle shaking at 4 °C. Insoluble
material was removed by centrifugation (12 000× g, 10 min, 4 °C) and
28 S. Lefort et al. / Virology 408 (2010) 14–30supernatantwas used for immunoprecipitation experiments.Whole-cell
protein extracts were prepared by heating equal volume of supernatants
and 2X SDS-loading buffer at 95 °C for 5 min.
Cell extracts for detection of sumoylated forms of K-bZIP
Fivemillion of nuclofected-BJAB and TREx-BCBL-1-Rtawere induced
with 1 μg/ml doxycyclin, in the presence of 1 μMof trichostatin A (TSA)
(Sigma-Aldrich Canada) and 5 μM of β-nicotinamide adenine dinucle-
otide (β-NAD) (Sigma-Aldrich). Cells were then lysed in 1 ml of SUMO
buffer (mix solution I (5% SDS, 0.15 M Tris–Cl pH 6.8, 30% glycerol) and
II (25 mM Tris–Cl pH 8.3, 50 mMNaCl, 0.5% deoxycholic acid, 0.1% SDS)
in a ratio of 1:3 and then added with 15 mM N-ethylmaleimide (NEM),
0.5% Nonidet P-40 and 1 protease inhibitor mixture. Cell lysates were
incubated under gentle shaking for 45 min at 4 °C, brieﬂy sonicated,
insoluble material was removed by centrifugation (12 000× g, 10 min,
4 °C) and supernatant was used for immunoprecipitation experiments.
Whole-cell protein extracts were prepared by heating equal volume of
proteins and 2X SDS-loading buffer at 95 °C for 5 min. Transfected HEK
293T cells were lysed and analyzed as BJAB and TREx-BCBL-1-Rta cells.
Cell extracts for acetylated K-bZIP detection
Fifteen million of BJAB and BCBL-1 were stimulated with 20 ng/ml
of phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) and
0.3 mM butyric acid (Sigma-Aldrich) for 6 and 24 h, in the presence
of 1 μM of TSA and 5 μM of β-NAD. Cells were then lysed in 1 ml of
RIPA buffer, added with TSA and β-NAD, and incubated under gentle
shaking, for 45 min at 4 °C. Insoluble material was removed by
centrifugation (12 000× g, 10 min, 4 °C) and supernatant was used for
immunoprecipitation experiments. Whole-cell protein extracts were
prepared by heating equal volume of proteins and 2X SDS-loading
buffer at 95 °C for 5 min. Transfected HEK 293T cells were lysed and
analyzed as BJAB and BCBL-1 cells.Nuclear extracts
HEK 293T were transfected with K8 expression vectors using
calcium phosphate in 10-cm plates. One day after transfection, the cells
were treated for 8 h with IFN alpha (1000 U/ml). Cell pellets were
resuspended in 400 μl of Buffer A [10 mM HEPES pH 7.9, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF] and then
incubated for 10 min on ice. Twenty-ﬁve microliters of NP-40 (10%)
was added and nuclei were sedimented by centrifuging the samples at
12000× g for 30 s. The nuclear pellets were resuspended in 50 μl of
Buffer B [20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, 1 mM PMSF] and incubated on a rocker for 15 min at 4 °C.
The suspensions were clariﬁed by centrifugation at 13000× g for 5 min.
The nuclear extracts (supernatants) were isolated and the protein
content estimated using the BCA Protein Assay Kit (Pierce).
DNA afﬁnity binding assay
This method was previously described (Lefort et al., 2007). Brieﬂy,
a biotinylated oligonucleotide containing the ISRE region of the 2′,5′-
OAS promoter (5′-CTCCTCCCTTCTGAGGAAACGAAACCAACAGCAG-3′)
was annealed with the corresponding antisense oligonucleotide in 1x
SSC buffer (0.15 M NaCl, 15 mM sodium citrate). Biotinylated DNA
oligonucleotides were mixed with 150 μg of nuclear extracts in 500 μl
of binding buffer containing 20 mM Tris–HCl, pH 7.5, 75 mM KCl,
1 mM dithiothreitol, and 5 mg/ml bovine serum albumin in presence
of 13% glycerol and 20 μg of poly (dI-dC) and incubated for 25 min at
room temperature. Then, streptavidin-conjugated magnetic beads
(Roche), washed three times with 400 μl of 1× binding buffer, were
added to the reactionmixture and incubated for 30 min at 4 °C and for10 min at room temperature with mixing by rotation. The beads were
collected using a magnet and washed three times with 500 μl of
binding buffer. The bound proteins were eluted from the beads by
boiling in Lamelli sample buffer and were resolved on 7.5% SDS-PAGE
followed by western blot using anti-K-bZIP (gift from H.Gruffat)
(Portes-Sentis et al., 2001), anti-STAT1, anti-STAT2, anti-P-STAT1
(Tyr701), anti-P-STAT2 (Tyr690), anti-IRF9 (Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, USA) antibodies.
Immunoprecipitation and immunoblot analysis
For immunoprecipitation experiments, equal protein amounts of
whole-cell extractswere incubatedwithanexcessof anti-K-bZIPantibody
for 1 hour at 4 °C followed by incubationwith protein A-agarose beads for
3 h at 4 °C, washed three times with lysis buffer, suspended in 1× SDS
buffer and heated for 5 min at 95 °C. Proteins fromwhole-cell extracts or
immunoprecipitated samples were resolved by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto nitrocellulose mem-
brane (Bio-Rad, Mississauga, Ontario, Canada). Non-speciﬁc sites were
blocked by incubating themembranes in PBS containing 0.05% Tween-20
(PBS-T) and 5% nonfat dry milk for 1 h followed by incubation with
primary antibodies, (mouse anti-myc (9E10), rabbit anti-CBP (Santa Cruz
Biotechnology) and mouse anti-acetylated-lysine (Ac-K-103) (Cell
Signaling)) or in PBS-T containing 5% BSA for phosphospeciﬁc antibodies
(Santa Cruz). After three 5-min washes in PBS-T, the membranes were
incubated for 1 h with HRP-conjugated goat anti-rabbit or goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA,
USA) in blocking solution. Immunoreactive proteins were visualized by
enhanced chemiluminescence (ECL) (Perkin Elmer Life Sciences, ON,
Canada).
HAT activity assay
HAT activity was determined using the colorimetric HAT activity
assay kit (BioVision Inc., Mountain View, CA). Nuclear extracts (50 μg)
from transfected cells treated with or without IFNα were assayed for
HAT activity. The reactionwas startedby adding substrate to the nuclear
lysates, including active HATs, and incubated at 37 °C for 1–3 h. Activity
was analyzed in a micro plate reader at 440 nm according to the kit
instructions.
Statistical analysis
Statistical analysis was performed with the aid of the Graph Pad In
Stat software using analysis of variance or unpaired Student t-test.
Statistical signiﬁcance was achieved when the p value b0.05.
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